RALEIGH, N.C., April 11, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the pricing of an underwritten public offering by the Company and a selling stockholder of 12,000,000 shares of common stock at a public offering price of $5.00 per share. In addition, underwriters have a 30-day option to purchase up to an additional 1,800,000 shares of common stock from a selling stockholder at the public offering price less the underwriting discount. The Company anticipates its gross proceeds from the offering, before deducting the underwriter discounts and commission and other offering expenses, to be $50.0 million. BDSI will not receive any of the proceeds from sale of the shares of common stock by the selling stockholder. The offering is expected to close on or about April 15, 2019, subject to customary closing conditions.

Cantor Fitzgerald & Co. and SunTrust Robinson Humphrey, Inc. are acting as joint book-running managers for the offering. Roth Capital Partners and H.C. Wainwright & Co., LLC are acting as co-managers for the offering.

ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology, to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs, including its products BELBUCA® and Symproic®. BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, opioid dependence and opioid induced constipation.